Novartis Piqray data show survival benefit for patients with HR+/HER2- advanced breast cancer with a…
Novartis announced results of the final overall survival (OS) analysis from the SOLAR-1 trial, which evaluated Piqray (alpelisib) in combination with fulvestrant, compared to…
Read More...
Read More...
